Preclinical pharmacokinetics and in vitro metabolism of BMS-605339: A novel HCV NS3 protease inhibitor

Journal of Pharmaceutical Sciences

Volumn 103, Issue 6, 2014, Pages 1891-1902

  Jenkins, Susan ^a   Scola, Paul ^a   McPhee, Fiona ^a   Knipe, Jay ^a   Gesenberg, Christoph ^a   Sinz, Michael ^a   Arora, Vinod ^a   Pilcher, Gary ^a   Santone, Kenneth ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

ADME; hepatic clearance; in vitro in vivo correlations (IVIVC); metabolism; preclinical pharmacokinetics; oral absorption; protease

Indexed keywords

BMS 605339; CYTOCHROME P450 3A4; ISOQUINOLINE; MULTIDRUG RESISTANCE PROTEIN; NONSTRUCTURAL PROTEIN 3; O DEMETHYLASE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; BMS-605339; ISOQUINOLINE DERIVATIVE; NS3 PROTEIN, HEPATITIS C VIRUS; SULFONAMIDE; VIRUS PROTEIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEVELOPMENT; DRUG EXPOSURE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG UPTAKE; ENZYME INHIBITION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER BLOOD FLOW; LIVER CELL; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PHARMACOKINETICS; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOAVAILABILITY; CACO 2 CELL LINE; DOG; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; DOGS; HUMANS; IN VITRO TECHNIQUES; ISOQUINOLINES; MICE; MICE, INBRED BALB C; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84901277262     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23959     Document Type: Article

References (29)

1. Shepard CW, Finelli L, Alter MJ,. 2005. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5 (9): 558-567.
2. Kim WR,. 2002. Global epidemiology and burden of hepatitis C. Microbes Infect 4: 1219-1225.
3. Liang TJ, Heller T,. 2004. Pathogenesis of hepatitis C-Associated hepatocellular carcinoma. Gastroenterology 127 (5): S62-S71.
4. Hajarizadeh B, Grebely J, Dore GJ,. 2013. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 10 (9): 553-562.
5. Scola PM, Wang AX, Good AC, Sun LQ, Combrink KD, Campbell JA, Chen J, Tu Y, Sin N, Venables BL, Sit SY, Chen Y, Cocuzza A, Bilder DM, D'Andrea S, Zheng B, Hewawasam P, Ding M, Thuring J, Hernandez D, Yu F, Falk P, Zhai G, Sheaffer AK, Chen C, Lee MS, Barry D, Knipe JO, Han YH, Jenkins S, Gesenberg C, Sinz MW, Santone KS, Zvyaga T, Rajamani R, Klei HE, Colonno RJ, Grasela DM, Hughes E, Chien C, Adams S, Levesque PC, Li D, Zhu J, Meanwell NA, McPhee F,. 2013. Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection. J Med Chem 57 (5): 1708-1729.
6. McPhee F, Good AC, Campbell JA, Sheaffer A, Wang AX, Knipe JO, Gesenburg C, Hughes E, Bounous D, Klei HE, Zhai G, Hernandez D, Yu F, Tu Y, Chen J, Sit S-Y, Ripka A, Chen Y, Thuring J, Hewawasam P, Sun L-Q, Ding M, D'Andrea SV, Zheng Z, Sin N, Venables BL, Combrink K, Levine S, Prendegast J, Dunaj C, Lee M, Barry D, Friborg J, Mosure K, Phillips T, Arora VK, Shu Y-Z, Grasela D, Meanwell NA, Colonno R, Scola PM,. 2009. The discovery and early development of the HCV NS3 protease inhibitor BMS-605339 (abstract 55). Global Antiviral J 5 (Supplement 1): 2.
7. Siissalo S, Laitinen L, Koljonen M, Vellonen KS, Kortejarvi H, Urtti A, Hirvonen J, Kaukonen AM,. 2007. Effect of cell differentiation and passage number on the expression of efflux proteins in wild type and vinblastine-induced Caco-2 cell lines. Eur J Pharm Biopharm 67 (2): 548-554.
8. Chen C, Liu X, Smith BJ,. 2003. Utility of Mdr1-gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development. Curr Drug Metab 4 (4): 272-291.
9. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, Sugiyama Y,. 1997. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73 (2): 147-171.
10. Jones HM, Houston JB,. 2004. Substrate depletion approach for determining in vitro metabolic clearance: Time dependencies in hepatocyte and microsomal incubations. Drug Metab Dispos 32 (9): 973-982.
11. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P,. 1997. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Expl Ther 283 (1): 46-58.
12. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP,. 1997. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13 (4): 407-484.
13. Davies B, Morris T,. 1993. Physiological parameters in laboratory animals and humans. Pharm Res 10 (7): 1093-1095.
14. Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bos M, Cameron DR, Cartier M, Cordingley MG, Faucher AM, Goudreau N, Kawai SH, Kukolj G, Lagace L, LaPlante SR, Narjes H, Poupart MA, Rancourt J, Sentjens RE, St George R, Simoneau B, Steinmann G, Thibeault D, Tsantrizos YS, Weldon SM, Yong CL, Llinas-Brunet M,. 2003. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426 (6963): 186-189.
15. Perni RB, Almquist SJ, Byrn RA, Chandorkar G, Chaturvedi PR, Courtney LF, Decker CJ, Dinehart K, Gates CA, Harbeson SL, Heiser A, Kalkeri G, Kolaczkowski E, Lin K, Luong YP, Rao BG, Taylor WP, Thomson JA, Tung RD, Wei Y, Kwong AD, Lin C,. 2006. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 50 (3): 899-909.
16. Kunta JR, Sinko PJ,. 2004. Intestinal drug transporters: In vivo function and clinical importance. Curr Drug Metab 5 (1): 109-124.
17. Beaumont K, Harper A, Smith DA, Bennett J,. 2000. The role of P-glycoprotein in determining the oral absorption and clearance of the NK2 antagonist, UK-224,671. Eur J Pharm Sci 12 (1): 41-50.
18. Huang C, Zheng M, Yang Z, Rodrigues AD, Marathe P,. 2008. Projection of exposure and efficacious dose prior to first-in-human studies: How successful have we been? Pharm Res 25 (4): 713-726.
19. Balimane PV, Han YH, Chong S,. 2006. Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J 8 (1): E1-E13.
20. Hendrikx JJMA, Lagas JS, Rosing H, Schellens JHM, Beijnen JH, Schinkel AH,. 2013. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel. Int J Cancer 132 (10): 2439-2447.
21. Lan LB, Dalton JT, Schuetz EG,. 2000. Mdr1 limits CYP3A metabolism in vivo. Mol Pharm 58 (4): 863-869.
22. Perloff MD, von Moltke LL, Cotreau MM, Greenblatt DJ,. 1999. Unchanged cytochrome P450 3A (CYP3A) expression and metabolism of midazolam, triazolam, and dexamethasone in mdr(-/-) mouse liver microsomes. Biochem Pharmacol 57 (11): 1227-1232.
23. Berezhkovskiy LM,. 2011. The influence of hepatic transport on the distribution volumes and mean residence time of drug in the body and the accuracy of estimating these parameters by the traditional pharmacokinetic calculations. J Pharm Sci 100 (11): 5031-5047.
24. Koike K,. 2010. Animal models for hepatitis C and related liver disease. Hepatol Res 40 (1): 69-82.
25. Seiwert SD, Andrews SW, Jiang Y, Serebryany V, Tan H, Kossen K, Rajagopalan PT, Misialek S, Stevens SK, Stoycheva A, Hong J, Lim SR, Qin X, Rieger R, Condroski KR, Zhang H, Do MG, Lemieux C, Hingorani GP, Hartley DP, Josey JA, Pan L, Beigelman L, Blatt LM,. 2008. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother 52 (12): 4432-4441.
26. Cheng KC,. 2009. Use of pre-clinical in vitro and in vivo pharmacokinetics for the selection of a potent hepatitis C virus protease inhibitor, boceprevir, for clinical development. Lett Drug Design Discov 6 (4): 312-318.
27. Scola PM, Sun LQ, Wang AX, Chen J, Sin N, Venables BL, Sit SY, Chen Y, Cocuzza A, Bilder DM, D'Andrea SV, Zheng B, Hewawasam P, Tu Y, Friborg J, Falk P, Hernandez D, Levine S, Chen C, Yu F, Sheaffer AK, Zhai G, Barry D, Knipe JO, Han YH, Schartman R, Donoso M, Mosure K, Sinz MW, Zvyaga T, Good AC, Rajamani R, Kish K, Tredup J, Klei HE, Gao Q, Mueller L, Colonno LJ, Grasela DM, Adams SP, Loy J, Levesque PC, Sun H, Shi H, Sun L, Warner W, Li D, Zhu J, Meanwell NA, McPhee F,. 2014. The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection. J Med Chem 57 (5): 1730-1752.
28. Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Hu W, Eley T, McPhee F, Hughes E, Kumada H,. 2013. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 58 (4): 655-662.
29. Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, Watanabe H, McPhee F, Hughes E, Kumada H,. 2012. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 55 (3): 742-748.